PAIN THERAPEUTICS, INC.
PTI-125, a small molecule therapeutic that binds filamin A to block Alzheimer's disease pathways
- Sector
- Biotech
- Headquarters
- AUSTIN, TX
- Latest Form D
- $1.1M, Aug 2018
- Total capital
- $4.6M
- Federal grants
- $3.5M
- 2 awards · 2017–2018
- Rank in peer group#276 of 514
- Private capital raised
- $1.1M
- 1 Form D · last Aug 2018
- 98 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 9
- 23 pending · first 2016
- Rank in peer group#35 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Additional costs related to formulation, chronic tox and general development of PTI-125$3.2M
- Private capital raisedForm D · SEC · 1st filing$1.1M
- Federal grantHealth and Human S · Phase I · Development of PTI DX a blood based diagnostic for Alzheimer s disease$295K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
12months
from PAIN THERAPEUTICS, INC.’s first federal award to its first private round.
- First federal award · Sep 2017
- Health and Human S · $295K
- First Form D · Aug 2018
- $1.1M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#35 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Remi BarbierResearcherExecutive Officer, DirectorLinked by 3 patents
- Michael O'DonnellDirectorNamed in SEC Form D filings
- Nadav FriedmannExecutive Officer, DirectorNamed in SEC Form D filings
- Patrick ScannonDirectorNamed in SEC Form D filings
- Robert GussinDirectorNamed in SEC Form D filings
- Saira RamasastryDirectorNamed in SEC Form D filings
Show all 7 people
- Sanford RobertsonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 9 granted of 32- GrantedAlzheimer's Disease Assay In A Living PatientUSPTOUS 11,385,221
- GrantedSolid Polymorphs Of A Flna-binding Compound And Its Hydrochloride SaltsUSPTOUS 11,370,791
- GrantedCocrystals Of Naloxone And NaltrexoneUSPTOUS 11,096,936
Show all 32 patent records
- Alzheimer's Disease Assay In A Living PatientJul 12, 2022 · US 11,385,221Granted
- Solid Polymorphs Of A Flna-binding Compound And Its Hydrochloride SaltsJun 28, 2022 · US 11,370,791Granted
- Cocrystals Of Naloxone And NaltrexoneAug 24, 2021 · US 11,096,936Granted
- Crystalline Salts Of Naloxone And NaltrexoneApr 20, 2021 · US 10,980,799Granted
- Method Of Inhibiting Tau PhosphorylationSep 1, 2020 · US 10,760,052Granted
- Method For Inhibiting Growth Of Cancer CellsJul 30, 2019 · US 10,363,239Granted
- Alzheimer's Disease Assay In A Living PatieneMar 5, 2019 · US 10,222,368Granted
- 4:3 Naltrexone: 5-METHYL-2-FURALDEHYDE CocrystalApr 18, 2017 · US 9,623,017Granted
- Method For Inhibiting Growth Of Cancer CellsSep 6, 2016 · US 9,433,604Granted
- Micronized Opioid Compositions, Formulations And Dosage Forms And Methods Of Making SameAug 11, 2016 · Application 15099823Pending
- Oral Dosage Forms With Therapeutically Active Agents In Controlled Release Cores And Immediate Release Gelatin Capsule CoatsJul 10, 2014 · Application 13949966Pending
- Oral Dosage Forms With Therapeutically Active Agents In Controlled Release Cores And Immediate Release Gelatin Capsule CoatsJul 3, 2014 · Application 14201367Pending
- Cocrystals Of Naloxone And NaltrexoneApplication PCTUS2016053695Pending
- Method For Inhibiting Growth Of Cancer CellsApplication PCTUS2014058863Pending
- Solid Polymorphs Of A Flna-binding Compound And Its Hydrochloride SaltsApplication 62808609Pending
- Solid Polymorphs Of A Flna-binding Compound And Its Hydrochloride SaltsApplication PCTUS2020019305Pending
- Alzheimer's Disease Assay In A Living PatentApplication PCTUS2013050368Pending
- A Method Of Inhibiting Tau PhosphorylationApplication PCTUS2013050126Pending
- Filamin A Binding Anti-inflammatory And AnalgesicApplication PCTUS2009062860Pending
- Analgesic That Binds Filamin AApplication PCTUS2009062579Pending
- Dissolution Test Equipment And Methods For TestingApplication PCTUS2008085729Pending
- Methods For Conducting A Clinical TrialApplication PCTUS2008085721Pending
- Micronized Opioid Compositions, Formulations And Dosage Forms And Methods Of Making SameApplication PCTUS2008085738Pending
- Analgesia With Minimal Tolerance And Dependence By A Mu Opioid Receptor Agonist That Also Binds Filamin AApplication PCTUS2008082116Pending
- Disposable Column System For Purification Of Radiolabeled PolypeptidesApplication PCTUS2008081337Pending
- Methods For The Treatment Of Back PainApplication PCTUS2005010043Pending
- Methods And Materials Useful For The Treatment Of Arthritic Conditions, Inflammation Associated With A Chronic Condition Or Chronic PainApplication PCTUS2004034184Pending
- Method And Materials For The Treatment Of Pain Comprising Opioid AntagonistsApplication PCTUS2004011569Pending
- Inhibitors Abc Drug Transporters In Microbial CellsApplication PCTUS2002017153Pending
- Inhibitors Of Abc Drug Transporters In Cancer CellsApplication PCTUS2002017092Pending
- 4:3 Naltrexone: 5-METHYL-2-FURALDEHYDE CocrystalApplication PCTUS2015051849Pending
- Inhibitors Of Abc Drug Transporters At The Blood- Brain BarrierApplication PCTUS2001045367Pending
Related companies, and why
- AVENZOAR PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- Lipomedics Inc.Similar federal contract value in Biotech · null in contracts
- NAVEGA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- APPLIED BIOLOGICAL LABORATORIES, INC.Similar federal contract value in Biotech · null in contracts
- METANOIA BIO LLCSimilar federal contract value in Biotech · null in contracts
- THENDOR THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .